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Abstract
Background
The European Association for the Study of the Liver (EASL) criteria and the modified
Response Evaluation Criteria in Solid Tumors (mRECIST) are currently adopted to evaluate
radiological response in patients affected by HCC and treated with loco-regional proce-
dures. Several studies explored the validity of these measurements in predicting survival
but definitive data are still lacking.
Aim
To conduct a systematic review of studies exploring mRECIST and EASL criteria useful-
ness in predictive radiological response in HCC undergoing loco-regional therapies and
their validity in predicting survival.
Methods
A comprehensive search of the literature was performed in electronic databases EMBASE,
MEDLINE, COCHRANE LIBRARY, ASCO conferences and EASL conferences up to June
10, 2014. Our overall search strategy included terms for HCC, mRECIST, and EASL. Loco-
regional procedures included transarterial embolization (TAE), transarterial chemoemboli-
zation (TACE) and cryoablation. Inter-method agreement between EASL and mRECIST
was assessed using the k coefficient. For each criteria, overall survival was described in
responders vs. non-responders patients, considering all target lesions response.
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Results
Among 18 initially found publications, 7 reports including 1357 patients were considered eli-
gible. All studies were published as full-text articles. Proportion of responders according to
mRECIST and EASL criteria was 62.4% and 61.3%, respectively. In the pooled population,
1286 agreements were observed between the two methods (kappa statistics 0.928, 95%
confidence interval 0.912–0.944). HR for overall survival (responders versus non respond-
ers) according to mRECIST and EASL was 0.39 (95% confidence interval 0.26–0.61,
p<0.0001) and 0.38 (95% confidence interval 0.24–0.61, p<0.0001), respectively.
Conclusion
In this literature-based meta-analysis, mRECIST and EASL criteria showed very good
concordance in HCC patients undergoing loco-regional treatments. Objective response
according to both criteria confirms a strong prognostic value in terms of overall survival.
This prognostic value appears to be very similar between the two criteria.
Introduction
Hepatocellular carcinoma (HCC) represents today the fifth most common cancer diagnosis
and the third most common cause of cancer-related deaths [1]. Several risk factors have been
identified, including chronic hepatitis B and/or C viral infections, some inherited errors of
metabolism (i.e. hemocromatosis, Wilson’s disease, α1-antitrypsin deficiency), primary hepatic
immune disease and primary biliary cirrhosis [2]. More recently, a higher risk of liver cancer
development has also been reported in patients affected by systemic metabolic syndrome,
diabetes mellitus and non-alcoholic fatty liver disease [3]. Since 60%-80% of patients with
newly diagnosed HCC have cirrhosis of the liver, ultrasonography and AFP testing every 6–12
months are routinely performed to promote an early detection of malignant nodule transfor-
mation in asymptomatic patients. Despite screening programs fewer than 20% of HCC are cur-
able at the time of diagnosis and, given the presence of co-existent chronic liver disease in most
cases, valuation of the underlying liver function is essential in therapeutical decision, since it
can affect treatment efficacy and influence tolerability profile [4]. Current guidelines from the
American Association for the Study of Liver Diseases for intermediate-stage HCC recommend
loco-regional approaches for those patients with localized disease not suitable for surgical
resection/transplantation [5]. By inducing alteration in local temperature (radiofrequency abla-
tion, microwave ablation, cryoablation) or determining selective catheter-based infusion of
particles in cancer supplying arterial branches (chemoembolization), these procedures lead
to tumor necrosis and ensure disease control [6]. Radiological response is a well-recognised
surrogate endpoint in the assessment of treatment efficacy in phase II studies, whereas survival
remains crucial for phase III [7]. However conventional response evaluation criteria (WHO,
World Health Organization and RECIST, Response Evaluation Criteria in Solid Tumors)
have shown poor correlation with survival outcome in HCC patients, since they do not address
measures of antitumor activity other than tumour shrinkage (which is based on the sum
of bidimensional measurements of target lesions) [8]. To overcome this limitation, a modifica-
tion of the response assessment was developed starting from 2001 in order to include the
concept of tumour viability (tumoral tissue showing arterial uptake in the arterial phase of con-
trast-enhanced imaging techniques) and discriminate treatment efficacy from early failure [6].
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The European Association for the Study of the Liver (EASL) criteria and the modified
Response Evaluation Criteria in Solid Tumors (mRECIST) were adopted in the evaluation of
radiological response in patients affected by HCC and treated with loco-regional procedures.
EASL and mRECIST criteria differ from each others in terms of number of target lesions (all
versus< = 2) and calculation method (bidimensional versus unidimensional) as reported in
Table 1. Several studies [9, 10]indicate that evaluating the largest two lesions is generally the
most useful procedure for measuring TACE responses under both EASL and mRECIST, even
if the optimal number of lesions is not formally indicated in mRECIST criteria.
Up to now no large prospective validation is available for both mRECIST and EASL criteria
and further studies are needed to confirm the validity of these measurements and their correla-
tion with survival. Here we present a literature-based review gathering together all published
retrospective studies comparing mRECIST and EASL criteria predictivity of tumor response
and survival outcomes.
Methods
Selection of studies
Study selection was conducted according to the preferred reporting items for systematic
reviews and meta-analyses (PRISMA) statement [11] (S1 PRISMA Checklist). A comprehen-
sive search of the literature was performed in electronic databases EMBASE, MEDLINE and
COCHRANE LIBRARY, from February 2010 up to June 2014. The references within the iden-
tified articles were then manually searched for additional studies. Our overall search strategy
included terms for HCC, mRECIST, and EASL. To be eligible for inclusion, studies had to met
the following criteria: (1) Loco-regional procedures included transarterial embolization (TAE),
transarterial chemoembolization (TACE) and cryoablation, (2) response assessment after loco-
regional treatments was evaluated according to both mRECIST and EASL criteria, (3) availabil-
ity of data about overall survival and (4) reported k coefficient as measurement of mRECIST
and EASL concordance, or availability (in the text or in a table) of the information needed to
calculate it. Moreover, meeting abstracts presented in the most recent International Meetings
(American Society of Clinical Oncology, American Association for the Study of Liver Diseases,
and European Association for the Study of the Liver), personal presentation and no published
data from ongoing study were explored and included if the above criteria were respected. No
language limitation were observed, as all selected works were written in English.
Table 1. Comparison betweenmRECIST and EASL criteria for HCC10.
mRECIST criteria EASL criteria
• CR: No intratumoral arterial enhancement in all
target lesions.
• CR: Absence of any viable lesions (enhancing
lesion on arterial phase of T1 post-contrast
sequence on dynamic abdominal magnetic
resonance imaging study).
• PR:  30% reduction of the sum of diameters of
viable (enhancement in the arterial phase) target
lesions.
• PR:  50% reduction of the sum of diameters of
viable target lesions.
• SD: Features classifiable as neither partial
response nor progressive disease.
• SD: Features classifiable as neither partial
response nor progressive disease.
• PD:  20% increase of the sum of the diameters of
viable target lesions.
• PD:  25% increase of the sum of the diameters
of viable target lesions.
Abbrevation: HCC, hepatocellular carcinoma; mRECIST, modified Response Evaluation Criteria in Solid
Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
doi:10.1371/journal.pone.0133488.t001
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Data extraction, clinical end points and quality assessment
By reading the full texts of the selected citations, two investigators (M.S. and L.D.) indepen-
dently evaluated each identified for eligibility and quality, and then extracted the following
data: name of all authors, year of publication, number of enrolled patients, type of loco-regional
treatment, reported hazard ratio (HR) for overall survival (OS) according to mRECIST and
EASL criteria and k coefficient of concordance in each study. Since progression free survival
was not available for all studies, differently from overall survival outcome, these data were not
extrapolated.
Statistical analysis
After data were abstracted, the authors proceed to their analysis using Review Manager (Rev-
Man 5), the software used for preparing and maintaining Cochrane Reviews. Inter-methods
concordance between similar categorical items of the two criteria was measured using the k
coefficient. The strength of agreement based on k values was interpreted as follows: k less than
0.21, poor; k of 0.21–0.40, fair; k of 0.41–0.60, moderate; k of 0.61–0.80, good; and k greater
than 0.80, excellent [12]. Hazard ratio (HR) for overall survival were used for meta-analysis,
considering responders (complete or partial response) versus non responders patients, using
the generic inverse variance outcome type in RevMan. To account for the heterogeneity of
studies, a random-effects model was applied. For both mRECIST and EASL criteria, funnel
plots were used to grossly exclude publication bias.
Results
Of 18 titles identified in the original search, 7 reports including 1357 patients were considered
eligible for analysis (Fig 1). All trials, available as full-text articles, have been conducted retro-
spectively. The overall collection data period was March 2000 –June 2014. Diagnosis of HCC
was confirmed by biopsy or radiologic imaging techniques according to the guidelines in each
study.
11 studies were considered not eligible for analysis, as reported in Table 2. One was focused
on the prognostic role of number of target lesions more than on that of response criteria [13].
Another study reported response and survival data at specific time point, so that it was not pos-
sible to extract the overall data [14]. In five works authors chose RECIST 1.0, RECIST 1.1 or
volumetric RECIST version as comparator response criteria [15–19]. Lee IJ et al focused on
correlation between radiologic response (according to WHO, RECIST, mRECIST and EASL
criteria) and pathologic post resection viability [20]. Finally three studies compared the prog-
nostic value of all known criteria (WHO, RECIST, mRECIST and EASL) to each other but it
was not possible to draw all parameter we need for analysis [10, 21, 22]. However, data from
one of these excluded studies [19] were obtained from a second, more recent publication [23]
describing the same series of patients.
Baseline patients characteristics were homogeneous among retrospective cohorts and are
listed in Table 3. General exclusions criteria were: inadequate target lesion (infiltrative pattern
or largest lesion<1 cm); (2) presence of an additional primary malignancy in other organ; (3)
presence of extrahepatic lesions; (4) presence of uncontrolled functional or metabolic disease.
Of note, only two studies [13, 22] limited the inclusion to Child-Pugh class A patients, while
the other studies included a minority of Child-Pugh B patients, and even a small percentage of
Child-Pugh C patients in 1 case [9]. Most enrolled patients underwent TACE as initial therapy
and then repeated TACE on demand at 4–8 weeks after the first cycle. One study [9] used
drug-eluting beads (DEB) TACE. In all cases femoral artery approach was preferred. Arteries
selective catheterization was followed by TACE following the internal guidelines of the
Meta-Analysis for EASL vs RECIST Criteria in HCC Patients
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different institution. Chemotherapeutics agents were doxorubicin (in three studies [9, 23, 24]
or cisplatin (in two studies [22, 25]. Only one among the considered studies used cryoablation
as loco-regional procedure [26]. Tumour measurements were performed according to the
EASL and mRECIST criteria and assessment of response was carried out by contrast-enhanced
Table 2. Study excluded frommetanalysis.
Kim BK, et al. Clin Cancer Res. 2013
Boatta E, et al Indian J Radiol Imaging. 2013
Shuster A, et al J Vasc Interv Radiol. 2013
Price TR, et al Cancer. 2012
Riaz A, et al JAMA. 2010
Lin M, et al J Vasc Interv Radiol. 2012
Yozo Saro, et al Upsala Journal of Medical Sciences. 2013
Lee IJ, et al Gastrointestinal Cancers Symposium J Clin Oncol 2013
Shim JH, et al Radiology. 2012
Meza-Junco J, et al Cancer Treat Rev. 2012
Duke E, et al J Vasc Interv Radiol. 2010
doi:10.1371/journal.pone.0133488.t002
Fig 1. Flow diagram of study selection.
doi:10.1371/journal.pone.0133488.g001
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spiral computed tomography (CT) or gadolinium-enhanced magnetic resonance imaging
(MRI) after 4–8 weeks from treatment, depending on each study. In detail, as reported in
Table 4, the procedure used was CT in the majority of cases, with the exception of one study
using MRI [9] and two studies [13, 25] using CT or MRI (mostly CT in the study by Gillmore
et al; no further details in the study by Kim BK et al). As shown in Table 4, most studies consid-
ered the overall response, while the study by Kim CJ et al [27] reported only the index lesion,
that is currently validated for follow-up of patients with HCC [15] (and it is recommended by
the American Association for the Study of Liver Diseases).
Response
Both criteria embraced the following four response categories: complete response (CR), partial
response (PR), stable disease (SD) and progressive disease (PD). Objective response (OR)
included both CR and PR. As reported in Table 1, according to RECIST, CR was defined as the
absence of arterially enhanced areas; PR and PD, as a greater than 30% decrease and a greater
than 20% increase, respectively, of the sum of the longest diameters of the enhancing target
lesions; and SD, as neither PR nor PD. According to EASL criteria, PR and PD were defined as
a greater than 50% decrease and a greater than 25% increase, respectively, of the sum of the
cross products of the enhancing target lesions. The appearance of new HCC lesions denoted
PD under both criteria, confirmed when their diameter exceeded 1 cm or when the lesion
became at least 1 cm larger on progressive scans.
Table 5 shows the response assessed with EASL criteria after loco-regional therapy adminis-
tration in the 7 considered studies. Table 6 shows the response assessed with mRECIST criteria
after loco-regional therapy administration in the same studies.
Table 3. Baseline patient characteristics.
Age Sex ECOG PS Child-Pugh BCLC stage Tumor number Treatment
Gillmore 67 M: 72 0: 43 A: 69 A: 6 1: 30 TAE: 57
F: 11 1: 25 B: 13 B: 38  2: 53 TACE: 26
2: 11 nr: 1 C: 36
Jung ES 59.6 M: 85 0: 24 A: 77 A: 37 1: 46 TACE: 114
F: 16 1: 66 B: 21 B: 38  2: 40
2: 8 nr: 1 C: 23
Kim BK 60 M: 290 0: 190 All Child A Not reported 1: 39 TACE: 292
F: 42 1: 102  2: 253
Prajapati HJ 61.7 M: 95 0: 49 A: 71 A: 14 1: 58 DEB TACE: 120
F: 25 1: 56 B: 41 B: 20  2: 62
2: 15 C: 8 C: 76
End: 10
Li H 60.5 M: 51 0: 44 A: 40 A: 4 Not reported Cryoablation: 64
F: 13 1: 8 B: 24 B: 30
2: 12 C: 30
Kim CJ 62.9 M: 283 0: 332 A: 249 A: 152 1: 176 TACE: 368
F: 85 1: 29 B: 118 B: 82  2: 192
2: 7 C: 0 C: 134
Choi J 62 M: 290 Not reported All Child A All BCLC B 2–3: 197 TACE: 332
F: 42  4: 135
Abbreviation: ECOG PS: Eastern cooperative oncology group performance status, BCLC: Barcelona Clinic Liver Cancer
doi:10.1371/journal.pone.0133488.t003
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The number of responders according to mRECIST and EASL criteria was 847 / 1357
(62.4%) and 832 / 1357 (61.3%), respectively.
Kappa statistics (available or calculated by data described in the paper in all the 7 studies)
showed very high concordance between responses assessed by using EASL and mRECIST
criteria (Table 7). In the pooled population of the 7 studies (Table 8), out of 1357 patients,
Table 4. Timing of instrumental assessment and lesions considered.
Reference Exam Timing Response
considered
Gillmore R,
et al
84% CT, 16% MRI Median 64 days (range 18–129) Overall response
Li H, et al CT Median 40 days (range, 26–80) Overall response
Prajapati
HJ, et al
MRI The median period between the DEB TACE therapies
and post-treatment assessment MRI scans was 33.5
days (range 0–113). In 61.7% (n = 74) of patients, MRI
scans (to assess treatment response) were carried out
after first DEB TACE with a median period of 33.50 days.
In 33.3% (n = 40) of patients, MRI scans were carried out
after second DEB TACE with the median period of 35
days. In 5% (n = 6) of patients, post-treatment response
was assessed using MRI scan carried out after third DEB
TACE (median of 27 days).
Overall response
Kim BK,
et al
CT or MRI Treatment responses were assessed 4 weeks after the
initial TACE.
Overall response
Jung ES,
et al
CT was performed at baseline and 3–4 weeks after
TACE, and wasused for response assessment. When
indicated, 15 (15.3%) patientsunderwentprimovist-
enhanced dynamic MRI to further clarifytumor viability.
We compared treatment responses between
baselineimaging at diagnosis and follow-up imaging at
early time point after 1–2 sessions of TACE.
Overall response
Kim CJ, et al CT Imaging follow-up (and hencemeasurement of the target
lesions) was performed at 1 month following each
treatment; subsequent scans were performed at
scheduled 2 to 3 month intervals as per standard of care.
For this analysis, even if several tumours were targeted
during the first or subsequent treatments with
chemoembolization or RFA, only the primary target
lesions were used to assess response and followed
longitudinally, even if those were not thelesions most
recently treated.
Target response
(overall not
reported)
Choi J, et al CT 1 month after the first TACE Overall response
CT: computed tomography; MRI: magnetic resonance imaging; TACE: trans-arterial chemo-embolization; DEB TACE: drug-eluting beads trans-arterial
chemo-embolization; RFA: radiofrequency ablation.
doi:10.1371/journal.pone.0133488.t004
Table 5. Response assessment according to EASL criteria.
References N° Pts CR PR SD PD
Gillmore R, et al 83 17 (20%) 32 (38%) 12 (14%) 22 (27%)
Li H, et al 64 10 (15,6%) 27 (42,2%) 18 (38,1%) 9 (14,1%)
Prajapati HJ, et al 120 24 (20%) 23 (19,2%) 40 (33,3%) 33 (27,5%)
Kim BK, et al 292 113 (38,7%) 106 (36,3%) 62 (21,2%) 11 (3,8%)
Jung ES, et al 114 34 (34,7%) 34 (34,7%) 25 (25,5%) 5 (5,1%)
Kim CJ, et al 368 162 (44,0%) 80 (21,7%) 59 (16.0%) 67 (18,2%)
Choi J et al 332 64 (19,3%) 106 (31,9%) 132 (39,8%) 30 (9,0%)
Abbrevation: CR: complete response; PR: partial response; SD: stable disease; PD: progression disease
doi:10.1371/journal.pone.0133488.t005
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1286 agreements were observed between the two methods (94.77% of the observations, kappa
statistics 0.928, 95% confidence interval 0.912–0.944).
Survival
With the limitation of the small number of studies included, funnel plots for both EASL and
mRECIST estimates did not show asymmetry (S1 Fig and S2 Fig), so there was no clear evi-
dence of publication bias.
Hazard Ratio for overall survival (responders versus non responders) according to mRE-
CIST criteria (Fig 2) was 0.39 (95% confidence interval 0.26–0.61, p<0.0001), with a statisti-
cally significant heterogeneity among the studies (I2 82%, p<0.00001).
Similarly, Hazard Ratio for overall survival (responders versus non responders) according
to EASL criteria (Fig 3) was 0.38 (95% confidence interval 0.24–0.61, p<0.0001), with a statisti-
cally significant heterogeneity among the studies (I2 84%, p<0.00001).
Discussion
Tumor response assessment is a cornerstone in cancer patient management, both in everyday
clinical practice and as auxillary surrogate end point of survival for the evaluation of treatment
efficacy in clinical studies.
Since new biological agents and loco-regional procedures exert their antitumoral activity by
inducing tumour necrosis, with rare changes in volume shrinkage, traditional WHO and
RECIST criteria do not always represent an appropriate tool for response evaluation, as they
Table 6. Response assessment according to mRECIST criteria.
References N° Pts CR PR SD PD
Gillmore R, et al 83 17 (20%) 31 (37%) 13 (16%) 22 (27%)
Li H, et al 64 10 (15,6%) 28 (43,8%) 17 (26,6%) 9 (14,1%)
Prajapati HJ, et al 120 24 (20%) 39 (32,5%) 24 (20%) 33 (27,5%)
Kim BK, et al 292 117 (40,1%) 93 (31,8%) 73 (25%) 9 (3,1%)
Jung ES, et al 114 34 (34,7%) 28 (28,6) 31 (31,6%) 5 (5,1%)
Kim CJ, et al 368 162 (44,0%) 88 (23,9%) 51 (13.9%) 67 (18,2%)
Choi J et al 332 64 (19,3%) 112 (33,7%) 126 (38,0%) 30 (9,0%)
Abbrevation: CR: complete response; PR: partial response; SD: stable disease; PD: progression disease
doi:10.1371/journal.pone.0133488.t006
Table 7. Inter-methods concordance between EASL andmRECIST criteria.
References N° Pts Treatment k value
Gillmore R, et al 83 TAE/TACE 0,983*
Li H, et al 64 Cryoablation 0,91
Prajapati HJ, et al 120 DEB TACE 0,82
Kim BK, et al 292 TACE 0,863
Jung ES, et al 114 TACE 0,883
Kim CJ, et al 368 TACE 0,969*
Choi J, et al 332 TACE 0,957
*calculated using the data reported in the paper
TAE: trans-arterial embolization; TACE: trans-arterial chemo-embolization; DEB TACE: drug-eluting beads
trans-arterial chemoembolization.
doi:10.1371/journal.pone.0133488.t007
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are based on dimensional criteria with no indication of lesion density changes. This concept
has been very clearly described in several studies where both WHO and RECIST showed poor
correlation with survival [8]. This observation, that can be assumed for most of solid cancer,
becomes extremely relevant in HCC management, for which antiangiogenic drugs (i.e. sorafe-
nib) and selective ablative procedures represent the standard of care for inoperable disease. To
overcome these limitations, the EASL and mRECIST criteria have been suggested to be a better
way of assessing tumor response in HCC patients. Several studies, recently reviewed [28], dem-
onstrated their superiority over conventional criteria. The evaluation of tumour viability, repre-
sents the most relevant change in EASL/mRECIST criteria compared to traditional WHO/
RECIST.
To the best of our knowledge, our meta-analysis is the first comprehensive paper aiming to
address the superiority in assessing response of one criterion over the other. Since WHO and
RECIST criteria are well recognized as inadequate, we only considered EASL and mRECIST
methods and compare their predictivity of survival. Our results show how both EASL and
mRECIST response evaluation methods can be of help in predicting long-term survival in
HCC patients treated with TACE, with no proven advantage of one method over the other.
Our meta-analysis also showed a statistically significant heterogeneity for both mRECIST and
EASL criteria. This statistical heterogeneity could be related to relevant differences between
the included studies, not only in terms of patients characteristics, but also in the technique
used for the treatment procedure, and in the timing of instrumental assessment that, as shown
in Table 4, was not the same among the series. However, each single study showed a better
Table 8. Agreement betweenmRECIST and EASL response in the 7 studies pooled.
mRECIST response*
CR PR SD PD
EASL response* CR 424 0 0 0 424
PR 4 379 25 0 408
SD 0 40 308 0 348
PD 0 0 2 175 177
428 419 335 175 1357
*overall response, with the exception of the study by Kim et al., where only target response was available. CR: complete response; PR: partial response;
SD: stable disease; PD: progressive disease.
doi:10.1371/journal.pone.0133488.t008
Fig 2. Forest plot for HR for overall survival (responders vs non responders) according to mRECIST criteria.
doi:10.1371/journal.pone.0133488.g002
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prognosis for responders compared to non-responders, with only quantitative heterogeneity in
the hazard ratio. Heterogeneity of collection data together with retrospective nature of included
studies, represent a large limitation for our work.
Give our results, we believe that EASL and mRECIST criteria deserve further evaluation as
response assessment methods in HCC patients undergoing TACE, and that larger prospective
trials should be encouraged in the future.
Conclusion
In this literature-based meta-analysis, mRECIST and EASL criteria showed a very good con-
cordance in HCC patients undergoing loco-regional treatments. Objective response according
to both criteria confirm a strong prognostic value in terms of overall survival. This prognostic
value appears to be very similar between the two methods.
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